Incb053914
Colorectal Cancer (CRC)
Incyte CorporationPhase 1Dormant
C
35/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 23/ 100
- Competitive Position
- 73/ 100
Competitive context
33 Active assets in the Colorectal Cancer (CRC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DARATUMUMAB Incyte Corporation | Phase 2 | B |
Pucotenlimab Sun Yat-sen University | Phase 3 | B |
Relatlimab Exelixis | Phase 2 | B |
Selinexor Karyopharm Therapeutics Inc | Phase 2 | B |
Bms-844203 Bristol-Myers Squibb | Phase 2 | CCC |
View all 43 →
Same molecule, other indications
Incb053914 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →